info-atbvac > Nosocomial pneumonia

Nosocomial pneumonia

Adjunction of inhaled amikacin to intravenous standard-of-care antibiotics do not modified short term prognosis of Ventilator Associated Pneumonia due to Gram-negative bacilli. ( Niederman MS. et al. )

Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial.
| Dr Olivier Leroy

The ESCMID recommendations published in 2017 (ATB-VAC 31/5/2017) are clear: the use of inhaled antibiotics in ICU should be prohibited. … Suite  

Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia. Results of a phase 3 trial. ( Kollef MH. et al. )

Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.
| Dr Jean-Pierre Bru

This randomised, controlled, double-blind, non-inferiority trial was conducted at 263 hospitals in 34 countries. Eligible patients were adults, undergoing mechanical … Suite